Table 1 Baseline characteristics of the two groups enrolled in current study.

From: The relationship of glycosylated hemoglobin A1c and Apolipoprotein A‑1 ratio on short-term prognosis in STEMI patients following PCI: a retrospective study

 

NO-MACEs

(n = 132)

MACEs

(n = 50)

T/ χ2/Z

P

Male, n (%)

112 (84.8)

40 (80.0)

0.619

0.431

Age, years

Medical history, n (%)

57.67 ± 11.60

62.70 ± 12.62

-2.550

0.012

Hypertension

68 (51.5)

26 (52.0)

0.003

0.953

Diabetes

37 (28.0)

29 (58.0)

14.092

< 0.001

Cerebral infarction

5 (3.8)

6 (12.0)

2.982

0.084

Prior PCI

15 (11.4)

8 (16.3)

0.793

0.373

Smoking

66 (50.0)

26 (52.0)

0.058

0.810

Drinking

38 (28.8)

13 (26.0)

0.049

0.894

Killip grade, n (%)

    

Grade I

91 (68.9)

20 (40.0)

24.598

< 0.001

Grade II

37 (28.0)

18 (36.0)

Grade III

4 (3.03)

10 (20.0)

Grade IV

0 (0.0)

2 (4.0)

TIMI grade, n (%)

    

Grade 0

43 (32.6)

24 (48.0)

5.402

0.148

Grade I

7 (5.3)

4 (8.0)

Grade II

13 (9.8)

2 (4.0)

Grade III

69 (52.3)

20 (40.0)

Artery lesions, n (%)

Multiple

Single

81 (61.36)

51 (38.64)

48 (96.00)

2 (4.00)

21.08

< 0.001

Systolic BP, mmHg

128.64 ± 23.13

123.680 ± 22.18

1.307

0.193

Diastolic BP, mmHg

76.12 ± 14.50

74.14 ± 13.40

0.832

0.407

LVEF, %

59.74 ± 9.59

51.72 ± 9.71

5.013

< 0.001

LVEDD, mm

52.72 ± 9.53

54.65 ± 8.87

-1.243

0.216

LVESD, mm

Laboratory tests

35.71 ± 7.90

39.39 ± 8.38

-2.760

0.006

HB, g/L

141.01 ± 18.76

133.28 ± 17.43

2.525

0.012

HCT, %

42.21 ± 5.15

40.17 ± 5.00

2.395

0.018

TNT-hs, pg/ml

Probnp, pg/ml

362.70(120.100,1828.0)

642.90(181.05,1772.00)

527.00(127.00,1892.00)

1382.00(331.52,3352.7)

-0.588

-2.178

0.556

0.029

TP, g/L

64.35 ± 5.32

63.59 ± 6.07

0.821

0.413

ALB, g/L

41.08 ± 3.81

38.84 ± 3.97

3.479

< 0.001

GLB, g/L

23.392 = ± 4.09

24.74 ± 4.16

-1.963

0.051

γ-GT, U/L

25.50 (17.00, 38.75)

29.00 (20.00, 67.00)

-2.07

0.038

ALP, IU/L

85.50 (72.00, 103.00)

88.00 (75.00, 97.00)

-0.19

0.851

UREA, mmol/L

5.34 ± 2.13

6.022 ± 1.92

-1.956

0.052

Cr, µmol/l

72.50 (63.67, 85.10)

73.350(65.57, 87.07)

-0.544

0.587

eGFR, mL/min/1.73m2

94.12 (82.75, 103.23)

90.35 (75.25, 101.53)

-1.45

0.148

CysC, mg/L

1.43 ± 4.65

1.07 ± 0.25

0.553

0.581

TC, mmol/l

4.08 ± 1.16

4.36 ± 1.10

-1.489

0.138

TG, mmol/L

1.73 ± 1.46

1.78 ± 1.08

-0.212

0.833

HDL-C, mmol/L

1.04 ± 0.22

1.06 ± 0.23

-0.370

0.712

LDL-C, mmol/l

2.52 ± 0.98

2.76 ± 1.03

-1.437

0.152

VLD, mmol/L

0.52 ± 0.48

0.610 ± 0.56

-1.063

0.289

ApoA-l, g/L

1.09 ± 0.17

1.14 ± 0.17

-1.574

0.117

ApoB, g/L

0.92 ± 0.30

0.99 ± 0.29

-1.489

0.138

Apoa, mg/dL

13.40 (6.25, 31.30)

13.60 (6.40, 27.80)

-0.11

0.912

FPG, mmol/l

6.13 ± 2.21

7.94 ± 3.01

-3.868

< 0.001

HbA1c, %

HbA1c/ApoA-1

Medications, n (%)

6.81 ± 1.77

6.31 ± 1.97

8.39 ± 2.29

7.45 ± 2.07

-4.403

-3.446

< 0.001

< 0.001

Aspirin

129 (97.7)

49 (98.0)

0.000

1.000

Clopidogrel

77 (58.3)

33 (66.0)

0.891

0.345

Tigrillo

50 (37.8)

17 (34.0)

0.235

0.628

Statins

129 (97.7)

49 (98.0)

0.000

1.000

Anticoagulants

34(87.2%)

73(81.1%)

1.163

0.603

Beta-blockers

64 (48.5)

33 (66.0)

4.469

0.035

ARNI/RASi

60 (45.4)

32 (64.0)

4.990

0.026

nicorandil

61 (46.2)

19 (38.0)

0.993

0.319

SGLT2i

38(28.8)

24(48.0)

5.959

0.015

Ivabradine

17(12.9)

11(22)

2.318

0.128

  1. 1MMHG-0.133 kPa; PCI, percutaneous coronary intervention; Killip grade, Killip cardiac function grade, TIMI grade, TIMI blood flow grade; SBP, systolic blood pressure; DBP, diabetes mellitus; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; HB, hemoglobin; HCT, hematocrit; TNT-hs, high-sensitivity troponin T; ProBNP, amino terminal brain natriuretic peptide precursor; TP, total serum protein; ALB, serum albumin; GLB, serum globulin; ALP, alkaline phosphatase; γ-GT, γ-transpeptidase; UREA, blood urea; Cr, serum creatinine; eGFR, estimated glomerular filtration rate; CysC, serum cystatin C; TC, total cholesterol; TG, triglyceride; HDL–C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; VLDL, very low density lipoprotein cholesterol; ApoA-1, apolipoprotein A-l; ApoB, apolipoprotein B; Apoa, apolipoprotein a; FPG, fasting blood glucose; HbA1c, glycosylated hemoglobin A1c; HbA1c/ApoA-1,glycosylated hemoglobin A1c/apolipoprotein A1; ARNI, angiotensin receptor-neprilysin inhibitor; RASi, renin-angiotensin system inhibitor; SGLT2i, sodium-glucose transporter 2 inhibitor. P<0.05 was considered as statistically significant.
Back to article page